Rapamycin

ID: ALA413

Chembl Id: CHEMBL413

Max Phase: Approved

First Approval: 1999

Molecular Formula: C51H79NO13

Molecular Weight: 914.19

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Fyarro | Hyftor | Npc-12g | Rapalimus | Rapamycin | Sirolimus | AY-22989 | L04AA10 | NSC-226080 | SM-88 COMPONENT SIROLIMUS | WY-090217

Trade Names(4): Fyarro | Hyftor | Rapamune | Sirolimus

Canonical SMILES:  CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

Standard InChI:  InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1

Standard InChI Key:  QFJCIRLUMZQUOT-HPLJOQBZSA-N

Alternative Forms

1. Parent:

   

   ALA413

   SIROLIMUS

Molecule Features

Natural Product: No

Oral: Yes

Chemical Probe: Yes

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: Yes

Chirality: Yes

Availability: Yes

Prodrug: No

Calculated Properties

Molecular Weight: 914.19

Molecular Weight (Monoisotopic): 913.5551

AlogP: 6.18

#Rotatable Bonds: 6

Polar Surface Area: 195.43

Molecular Species: NEUTRAL

HBA: 13

HBD: 3

#RO5 Violations: 3

HBA (Lipinski): 14

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.96

CX Basic pKa: ┄

CX LogP: 7.45

CX LogD: 7.45

Aromatic Rings: ┄

Heavy Atoms: 65

QED Weighted: 0.16

Np Likeness Score: 1.94

References

1. Rabinowitz M, Seneci P, Rossi T, Dal Cin M, Deal M, Terstappen G..  (2000)  Solid-phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands.,  10  (10): [PMID:10843203] [10.1016/s0960-894x(00)00104-9]

2. Chen Y, Nakanishi K, Merrill D, Eng CP, Molnar-Kimber KL, Failli A, Caggiano TJ.  (1995)  Synthesis and bioactivity of photolabile sirolimus (rapamycin) analogs,  5  (13): [10.1016/0960-894X(95)00223-G]

3. Dickman DA, Ding H, Li Q, Nilius AM, Balli DJ, Ballaron SJ, Trevillyan JM, Smith ML, Seif LS, Kim K, Sarthy A, Goldman RC, Plattner JJ, Bennani YL..  (2000)  Antifungal rapamycin analogues with reduced immunosuppressive activity.,  10  (13): [PMID:10888319] [10.1016/s0960-894x(00)00184-0]

4. Bastos CM, Gordon KA, Ocain TD..  (1998)  Synthesis and immunosuppressive activity of ruthenium complexes.,  8  (2): [PMID:9871643] [10.1016/s0960-894x(97)10205-0]

5. Wagner R, Rhoades TA, Or YS, Lane BC, Hsieh G, Mollison KW, Luly JR..  (1998)  32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.,  41  (11): [PMID:9599228] [10.1021/jm960066y]

6. Holt DA, Konialian AL, Brandt M, Levy MA, Bossard MJ, Luengo JI, Newman-Tarr T, Badger A.  (1993)  Structure-activity studies of nonmacrocyclic rapamycin derivatives,  3  (10): [10.1016/S0960-894X(01)80998-7]

7. Nelson FC, Stachel SJ, Eng CP, Sehgal SN..  (1999)  Manipulation of the C(22)-C(27) region of rapamycin: stability issues and biological implications.,  9  (2): [PMID:10021948] [10.1016/s0960-894x(98)00735-5]

8. Holt DA, Konialian-Beck AL, Oh H, Yen H, Rozamus LW, Krog AJ, Erhard KF, Ortiz E, Levy MA, Brandt M, Bossard MJ, Luengo JI.  (1994)  Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors,  4  (2): [10.1016/S0960-894X(01)80135-9]

9. Sedrani R, Jones LH, Jutzi-Eme AM, Schuler W, Cottens S..  (1999)  Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.,  9  (3): [PMID:10091702] [10.1016/s0960-894x(99)00007-4]

10. Hamilton GS, Steiner JP..  (1998)  Immunophilins: beyond immunosuppression.,  41  (26): [PMID:9857082] [10.1021/jm980307x]

11. Wang YH, Li Y, Li YH, Yang SL, Yang L..  (2005)  Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.,  15  (18): [PMID:15990295] [10.1016/j.bmcl.2005.06.015]

12. Nicolaou KC..  (2005)  Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.,  48  (18): [PMID:16134928] [10.1021/jm050524f]

13. Nicolaou KC..  (2005)  Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.,  48  (18): [PMID:16134928] [10.1021/jm050524f]

14. Wagner R, Mollison KW, Liu L, Henry CL, Rosenberg TA, Bamaung N, Tu N, Wiedeman PE, Or Y, Luly JR, Lane BC, Trevillyan J, Chen YW, Fey T, Hsieh G, Marsh K, Nuss M, Jacobson PB, Wilcox D, Carlson RP, Carter GW, Djuric SW..  (2005)  Rapamycin analogs with reduced systemic exposure.,  15  (23): [PMID:16185865] [10.1016/j.bmcl.2005.06.106]

15. Torregrossa J, Bubley GJ, Jones GB..  (2006)  Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.,  16  (23): [PMID:16971123] [10.1016/j.bmcl.2006.08.103]

16. Sellmyer MA, Stankunas K, Briesewitz R, Crabtree GR, Wandless TJ..  (2007)  Engineering small molecule specificity in nearly identical cellular environments.,  17  (10): [PMID:17383876] [10.1016/j.bmcl.2007.03.012]

17. Moda TL, Montanari CA, Andricopulo AD..  (2007)  Hologram QSAR model for the prediction of human oral bioavailability.,  15  (24): [PMID:17870541] [10.1016/j.bmc.2007.08.060]

18. Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J..  (2007)  Small molecule regulators of autophagy identified by an image-based high-throughput screen.,  104  (48): [PMID:18024584] [10.1073/pnas.0709695104]

19. Freyer AJ, Patil AD, Killmer L, Troupe N, Mentzer M, Carte B, Faucette L, Johnson RK..  (1997)  Three new pseudodistomins, piperidine alkaloids from the ascidian Pseudodistoma megalarva.,  60  (10): [PMID:9358640] [10.1021/np9701438]

20. Edwards SR, Wandless TJ..  (2007)  The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain.,  282  (18): [PMID:17350953] [10.1074/jbc.m700498200]

21. Van de Vijver P, Ostrowski T, Sproat B, Goebels J, Rutgeerts O, Van Aerschot A, Waer M, Herdewijn P..  (2008)  Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.,  51  (10): [PMID:18438987] [10.1021/jm8000746]

22. Accetta A, Corradini R, Sforza S, Tedeschi T, Brognara E, Borgatti M, Gambari R, Marchelli R..  (2009)  New uracil dimers showing erythroid differentiation inducing activities.,  52  (1): [PMID:19072686] [10.1021/jm800982q]

23. Landi M, Catelani G, D'Andrea F, Ghidini E, Amari G, Paola P, Bianchi N, Gambari R..  (2009)  Synthesis of glycose carbamides and evaluation of the induction of erythroid differentiation of human erythroleukemic K562 cells.,  44  (2): [PMID:18571290] [10.1016/j.ejmech.2008.05.001]

24. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ..  (2007)  Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.,  282  (33): [PMID:17562705] [10.1074/jbc.m704741200]

25. Pratt MR, Schwartz EC, Muir TW..  (2007)  Small-molecule-mediated rescue of protein function by an inducible proteolytic shunt.,  104  (27): [PMID:17563385] [10.1073/pnas.0700816104]

26. Uzcátegui NL, Carmona-Gutiérrez D, Denninger V, Schoenfeld C, Lang F, Figarella K, Duszenko M..  (2007)  Antiproliferative effect of dihydroxyacetone on Trypanosoma brucei bloodstream forms: cell cycle progression, subcellular alterations, and cell death.,  51  (11): [PMID:17682096] [10.1128/aac.00423-07]

27. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR..  (2007)  Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.,  51  (7): [PMID:17485501] [10.1128/aac.01602-06]

28. Zhuang D, Smedema M, Lemonte A, Book BK, Pescovitz MD, Wheat LJ..  (2008)  Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.,  52  (2): [PMID:18025114] [10.1128/aac.01096-07]

29. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P..  (2007)  The selectivity of protein kinase inhibitors: a further update.,  408  (3): [PMID:17850214] [10.1042/bj20070797]

30. Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K..  (2009)  Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.,  52  (22): [PMID:19848404] [10.1021/jm9012642]

31. Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K..  (2010)  Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.,  53  (1): [PMID:19928864] [10.1021/jm901427g]

32. Carr G, Williams DE, Díaz-Marrero AR, Patrick BO, Bottriell H, Balgi AD, Donohue E, Roberge M, Andersen RJ..  (2010)  Bafilomycins produced in culture by Streptomyces spp. isolated from marine habitats are potent inhibitors of autophagy.,  73  (3): [PMID:20028134] [10.1021/np900632r]

33. Freeman-Cook KD, Autry C, Borzillo G, Gordon D, Barbacci-Tobin E, Bernardo V, Briere D, Clark T, Corbett M, Jakubczak J, Kakar S, Knauth E, Lippa B, Luzzio MJ, Mansour M, Martinelli G, Marx M, Nelson K, Pandit J, Rajamohan F, Robinson S, Subramanyam C, Wei L, Wythes M, Morris J..  (2010)  Design of selective, ATP-competitive inhibitors of Akt.,  53  (12): [PMID:20481595] [10.1021/jm1003842]

34. Cohen MS, Hadjivassiliou H, Taunton J..  (2007)  A clickable inhibitor reveals context-dependent autoactivation of p90 RSK.,  3  (3): [PMID:17259979] [10.1038/nchembio859]

35. MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK..  (2006)  Identifying off-target effects and hidden phenotypes of drugs in human cells.,  2  (6): [PMID:16680159] [10.1038/nchembio790]

36. Schwartz EC, Saez L, Young MW, Muir TW..  (2007)  Post-translational enzyme activation in an animal via optimized conditional protein splicing.,  3  (1): [PMID:17128262] [10.1038/nchembio832]

37. Krakauer T, Buckley M, Issaq HJ, Fox SD..  (2010)  Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.,  54  (3): [PMID:20086156] [10.1128/aac.01015-09]

38. Davies SP, Reddy H, Caivano M, Cohen P..  (2000)  Specificity and mechanism of action of some commonly used protein kinase inhibitors.,  351  (1): [PMID:10998351] [10.1042/0264-6021:3510095]

39. Butcher RA, Bhullar BS, Perlstein EO, Marsischky G, LaBaer J, Schreiber SL..  (2006)  Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.,  2  (2): [PMID:16415861] [10.1038/nchembio762]

40. Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O'Kane CJ, Floto RA, Rubinsztein DC..  (2008)  Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.,  4  (5): [PMID:18391949] [10.1038/nchembio.79]

41. PubChem BioAssay data set, 

42. Sadovski O, Jaikaran AS, Samanta S, Fabian MR, Dowling RJ, Sonenberg N, Woolley GA..  (2010)  A collection of caged compounds for probing roles of local translation in neurobiology.,  18  (22): [PMID:20427189] [10.1016/j.bmc.2010.04.005]

43. Juli C, Sippel M, Jäger J, Thiele A, Weiwad M, Schweimer K, Rösch P, Steinert M, Sotriffer CA, Holzgrabe U..  (2011)  Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.,  54  (1): [PMID:21142106] [10.1021/jm101156y]

44. Dannaoui E, Schwarz P, Lortholary O..  (2009)  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.,  53  (8): [PMID:19451295] [10.1128/aac.00184-09]

45. Fourches D, Barnes JC, Day NC, Bradley P, Reed JZ, Tropsha A..  (2010)  Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.,  23  (1): [PMID:20014752] [10.1021/tx900326k]

46. Unpublished dataset, 

47.  (2008)  Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, 

48. Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW..  (2011)  Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.,  21  (7): [PMID:21353551] [10.1016/j.bmcl.2011.01.139]

49. Grkovic T, Blees JS, Colburn NH, Schmid T, Thomas CL, Henrich CJ, McMahon JB, Gustafson KR..  (2011)  Cryptocaryols A-H, α-pyrone-containing 1,3-polyols from Cryptocarya sp. implicated in stabilizing the tumor suppressor Pdcd4.,  74  (5): [PMID:21539301] [10.1021/np100918z]

50. PubChem BioAssay data set, 

51. Scott S. Auerbach, DrugMatrix¨ and ToxFX¨ Coordinator National Toxicology Program. DrugMatrix in vitro pharmacology data, 

52. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W..  (2011)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).,  7  (12): [PMID:22194678] [10.1371/journal.pcbi.1002310]

53. Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG, Shevlin G, Hickman M, Khambatta G, Bisonette RR, Fultz KE, Sankar S..  (2011)  Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.,  21  (22): [PMID:21978683] [10.1016/j.bmcl.2011.09.035]

54. Schuetz EG, Beck WT, Schuetz JD..  (1996)  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.,  49  (1): [PMID:8632764]

55. Nagy H, Goda K, Fenyvesi F, Bacsó Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabó G..  (2004)  Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.,  315  (1): [PMID:14985103] [10.1016/j.bbrc.2004.01.156]

56. Fehrenbach T, Cui Y, Faulstich H, Keppler D..  (2003)  Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins.,  368  (1): [PMID:14530907] [10.1007/s00210-003-0814-4]

57. Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, Ramtoola Z..  (2002)  Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate.,  303  (1): [PMID:12235265] [10.1124/jpet.102.036541]

58. Arceci RJ, Stieglitz K, Bierer BE..  (1992)  Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.,  80  (1): [PMID:1381629]

59. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, 

60. Brunhofer G, Fallarero A, Karlsson D, Batista-Gonzalez A, Shinde P, Gopi Mohan C, Vuorela P..  (2012)  Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.,  20  (22): [PMID:23062825] [10.1016/j.bmc.2012.09.040]

61. Koehler MF, Bergeron P, Blackwood E, Bowman KK, Chen YH, Deshmukh G, Ding X, Epler J, Lau K, Lee L, Liu L, Ly C, Malek S, Nonomiya J, Oeh J, Ortwine DF, Sampath D, Sideris S, Trinh L, Truong T, Wu J, Pei Z, Lyssikatos JP..  (2012)  Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.,  55  (24): [PMID:23199076] [10.1021/jm301389h]

62. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ..  (2013)  A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.,  451  (2): [PMID:23398362] [10.1042/bj20121418]

63. Martina MR, Tenori E, Bizzarri M, Menichetti S, Caminati G, Procacci P..  (2013)  The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a New class of nanomolar FKBP12 ligands.,  56  (3): [PMID:23301792] [10.1021/jm3015052]

64. PubChem BioAssay data set, 

65. PubChem BioAssay data set, 

66. Wang Y, Kirschner A, Fabian AK, Gopalakrishnan R, Kress C, Hoogeland B, Koch U, Kozany C, Bracher A, Hausch F..  (2013)  Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.,  56  (10): [PMID:23647266] [10.1021/jm400087k]

67. Genomics of Drug Sensitity in Cancer screening data, Wellcome Trust Sanger Institute,  [10.6019/CHEMBL1201861]

68. Chen W, Deng XY, Li Y, Yang LJ, Wan WC, Wang XQ, Zhang HB, Yang XD..  (2013)  Synthesis and cytotoxic activities of novel hybrid 2-phenyl-3-alkylbenzofuran and imidazole/triazole compounds.,  23  (15): [PMID:23800685] [10.1016/j.bmcl.2013.06.001]

69. Giordanetto F, Kihlberg J..  (2014)  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?,  57  (2): [PMID:24044773] [10.1021/jm400887j]

70. Cuccarese MF, Wang Y, Beuning PJ, O'Doherty GA..  (2014)  Cryptocaryol Structure-Activity Relationship Study of Cancer Cell Cytotoxicity and Ability to Stabilize PDCD4.,  5  (5): [PMID:24900873] [10.1021/ml4005039]

71. Salomé C, Ribeiro N, Chavagnan T, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L..  (2014)  Benzofuran derivatives as anticancer inhibitors of mTOR signaling.,  81  [PMID:24836070] [10.1016/j.ejmech.2014.05.014]

72. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

73. Du L, Robles AJ, King JB, Mooberry SL, Cichewicz RH..  (2014)  Cytotoxic dimeric epipolythiodiketopiperazines from the ascomycetous fungus Preussia typharum.,  77  (6): [PMID:24893224] [10.1021/np5002253]

74. Gibbs AC..  (2014)  Elements and modulation of functional dynamics.,  57  (19): [PMID:24913411] [10.1021/jm500325k]

75. Shakeel-u-Rehman, Rah B, Lone SH, Rasool RU, Farooq S, Nayak D, Chikan NA, Chakraborty S, Behl A, Mondhe DM, Goswami A, Bhat KA..  (2015)  Design and Synthesis of Antitumor Heck-Coupled Sclareol Analogues: Modulation of BH3 Family Members by SS-12 in Autophagy and Apoptotic Cell Death.,  58  (8): [PMID:25825934] [10.1021/jm501942m]

76. Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin CP, Xia M..  (2011)  Identification of clinically used drugs that activate pregnane X receptors.,  39  (1): [PMID:20966043] [10.1124/dmd.110.035105]

77. Drug metabolism data, 

78. Ma X, Lv X, Qiu N, Yang B, He Q, Hu Y..  (2015)  Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.,  23  (24): [PMID:26596710] [10.1016/j.bmc.2015.11.003]

79. Fraser C, Carragher NO, Unciti-Broceta A.  (2016)  eCF309: a potent, selective and cell-permeable mTOR inhibitor,  7  (3): [10.1039/C5MD00493D]

80. Yoon S, Kim JH, Yoon I, Kim C, Kim SE, Koh Y, Jeong SJ, Lee J, Kim S, Lee J..  (2016)  Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor.,  26  (13): [PMID:27209231] [10.1016/j.bmcl.2016.05.011]

81. WHO Anatomical Therapeutic Chemical Classification, 

82. British National Formulary (72nd edition), 

83.  (2012)  Substituted isoquinolin-1(2H)-ones, and methods of use thereof, 

84. DrugMatrix,  [10.6019/CHEMBL3885881]

85. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs.,  358  (6367): [PMID:29191878] [10.1126/science.aan4368]

86. Gao L, Zhang R, Lan J, Ning R, Wu D, Chen D, Zhao W..  (2016)  β-Dihydroagarofuran-Type Sesquiterpenes from the Seeds of Celastrus monospermus and Their Lifespan-Extending Effects on the Nematode Caenorhabditis elegans.,  79  (12): [PMID:28006915] [10.1021/acs.jnatprod.6b00648]

87. Wu S, Wang Y, Liu N, Dong G, Sheng C..  (2017)  Tackling Fungal Resistance by Biofilm Inhibitors.,  60  (6): [PMID:28051303] [10.1021/acs.jmedchem.6b01203]

88. Sun QZ, Lin GF, Li LL, Jin XT, Huang LY, Zhang G, Yang W, Chen K, Xiang R, Chen C, Wei YQ, Lu GW, Yang SY..  (2017)  Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.,  60  (14): [PMID:28692292] [10.1021/acs.jmedchem.7b00665]

89. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T..  (2012)  Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.,  40  (12): [PMID:22961681] [10.1124/dmd.112.047068]

90. Guo Q, Yu C, Zhang C, Li Y, Wang T, Huang Z, Wang X, Zhou W, Li Y, Qin Z, Wang C, Gao R, Nie Y, Ma Y, Shi Y, Zheng J, Yang S, Fan Y, Xiang R..  (2018)  Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer.,  61  (3): [PMID:29308895] [10.1021/acs.jmedchem.7b01402]

91. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W..  (2016)  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.,  21  (4): [PMID:26948801] [10.1016/j.drudis.2016.02.015]

92. Kinarivala N, Patel R, Boustany RM, Al-Ahmad A, Trippier PC..  (2017)  Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).,  60  (23): [PMID:29110485] [10.1021/acs.jmedchem.7b01199]

93. Yoon S, Kim JH, Koh Y, Tran PT, Ann J, Yoon I, Jang J, Kim WK, Lee S, Lee J, Kim S, Lee J..  (2017)  Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.,  25  (15): [PMID:28625715] [10.1016/j.bmc.2017.06.002]

94. Saidel MÉ, Dos Santos KC, Nagano LFP, Montanari CA, Leitão A..  (2017)  Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.,  27  (17): [PMID:28774426] [10.1016/j.bmcl.2017.07.061]

95. Solomon VR, Pundir S, Le HT, Lee H..  (2018)  Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.,  143  [PMID:29232580] [10.1016/j.ejmech.2017.11.097]

96. Yoon S, Zuo D, Kim JH, Yoon I, Ann J, Kim SE, Cho D, Kim WK, Lee S, Lee J, Kim S, Lee J..  (2018)  Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.,  26  (14): [PMID:30041947] [10.1016/j.bmc.2018.06.034]

97. Guduru SKR, Arya P..  (2018)  Synthesis and biological evaluation of rapamycin-derived, next generation small molecules.,  9  (1): [PMID:30108899] [10.1039/C7MD00474E]

98. Mostafa AS, Selim KB..  (2018)  Synthesis and anticancer activity of new dihydropyrimidinone derivatives.,  156  [PMID:30015070] [10.1016/j.ejmech.2018.07.004]

99. Rageot D, Bohnacker T, Melone A, Langlois JB, Borsari C, Hillmann P, Sele AM, Beaufils F, Zvelebil M, Hebeisen P, Löscher W, Burke J, Fabbro D, Wymann MP..  (2018)  Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.,  61  (22): [PMID:30359003] [10.1021/acs.jmedchem.8b01262]

100. Johannes Zuegg, Alysha Elliott, Maite Amado, Emma Cowie, Ali Hinton, Geraldine Kaeslin, Angela Kavanagh, Anne Kunert, Gabriell Lowe, Soumya Ramu, Janet Reid, Robin Trauer, Mathilde Desselle, Ruth Neale, Karl Hansford, Mark Blascovich, Matthew Cooper. CO-ADD screening of NIH NCI Natural Product Set III,  [10.6019/CHEMBL4296183]

101. Unpublished dataset, 

102. Bernhard Ellinger, Denisa Bojkova, Andrea Zaliani, Jindrich Cinatl, Carsten Claussen, Sandra Westhaus, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geisslinger, Philip Gribbon, Sandra Ciesek.  (2020)  Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection,  [10.21203/rs.3.rs-23951/v1]

103. Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson.  (2020)  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,  [10.1101/2020.04.21.054387]

104. David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al.  (2020)  A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,  [PMID:32353859] [10.1038/s41586-020-2286-9]

105. Egbert M, Whitty A, Keserű GM, Vajda S..  (2019)  Why Some Targets Benefit from beyond Rule of Five Drugs.,  62  (22): [PMID:31188592] [10.1021/acs.jmedchem.8b01732]

106. Xu Z, Zhao SJ, Liu Y..  (2019)  1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.,  183  [PMID:31546197] [10.1016/j.ejmech.2019.111700]

107. Hao T, Li Y, Fan S, Li W, Wang S, Li S, Cao R, Zhong W..  (2019)  Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent.,  175  [PMID:31082764] [10.1016/j.ejmech.2019.04.048]

108. Chen SR, Wang SW, Chang FR, Cheng YB..  (2019)  Anti-Lymphangiogenic Alkaloids from the Zoanthid Zoanthus vietnamensis Collected in Taiwan.,  82  (10): [PMID:31584818] [10.1021/acs.jnatprod.9b00451]

109. Peterková L, Kmoníčková E, Ruml T, Rimpelová S..  (2020)  Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.,  63  (5): [PMID:32030976] [10.1021/acs.jmedchem.9b01509]

110. Chen Y, Yuan X, Zhang W, Tang M, Zheng L, Wang F, Yan W, Yang S, Wei Y, He J, Chen L..  (2019)  Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.,  62  (3): [PMID:30629434] [10.1021/acs.jmedchem.8b01825]

111. Zheng H, Dong Y, Li L, Sun B, Liu L, Yuan H, Lou H..  (2016)  Novel Benzo[a]quinolizidine Analogs Induce Cancer Cell Death through Paraptosis and Apoptosis.,  59  (10): [PMID:27077446] [10.1021/acs.jmedchem.6b00484]

112. Abdel-Magid AF..  (2019)  Rapalogs Potential as Practical Alternatives to Rapamycin.,  10  (6): [PMID:31223435] [10.1021/acsmedchemlett.9b00215]

113. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

114. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani.  (2020)  Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen,  [10.6019/CHEMBL4495564]

115. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

116. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen.  (2020)  Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort,  [10.6019/CHEMBL4495565]

117. Chen Y, Li Q, Li Q, Xing S, Liu Y, Liu Y, Chen Y, Liu W, Feng F, Sun H..  (2020)  p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.,  63  (18): [PMID:32324396] [10.1021/acs.jmedchem.9b02038]

118. Kil YS, Risinger AL, Petersen CL, Mooberry SL, Cichewicz RH..  (2020)  Leucinostatins from Ophiocordyceps spp. and Purpureocillium spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer.,  83  (6): [PMID:32510949] [10.1021/acs.jnatprod.0c00404]

119. Huang HC,Chang WT,Lee MS,Chen HY,Chen YH,Lin CC,Lin MK.  (2021)  Three bufadienolides induce cell death in the human lung cancer cell line CL1-5 mainly through autophagy.,  31  [PMID:33246109] [10.1016/j.bmcl.2020.127715]

120. Yoon S,Kim JH,Kim SE,Kim C,Tran PT,Ann J,Koh Y,Jang J,Kim S,Moon HS,Kim WK,Lee S,Lee J,Kim S,Lee J.  (2016)  Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.,  59  (22): [PMID:27933890] [10.1021/acs.jmedchem.6b01190]

121. Miura K,Kawano S,Suto T,Sato T,Chida N,Simizu S.  (2021)  Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.,  34  [PMID:33549907] [10.1016/j.bmc.2021.116041]

122. Atack TC,Raymond DD,Blomquist CA,Pasaje CF,McCarren PR,Moroco J,Befekadu HB,Robinson FP,Pal D,Esherick LY,Ianari A,Niles JC,Sellers WR.  (2020)  Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35.,  11  (11): [PMID:33209191] [10.1021/acsmedchemlett.0c00272]

123. Rassias G,Leonardi S,Rigopoulou D,Vachlioti E,Afratis K,Piperigkou Z,Koutsakis C,Karamanos NK,Gavras H,Papaioannou D.  (2021)  Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?,  210  [PMID:33139111] [10.1016/j.ejmech.2020.112948]

124. Aizpurua JM,Miranda JI,Irastorza A,Torres E,Eceiza M,Sagartzazu-Aizpurua M,Ferrón P,Aldanondo G,Lasa-Fernández H,Marco-Moreno P,Dadie N,López de Munain A,Vallejo-Illarramendi A.  (2021)  Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress.,  213  [PMID:33493827] [10.1016/j.ejmech.2021.113160]

125. Scheuplein NJ,Bzdyl NM,Kibble EA,Lohr T,Holzgrabe U,Sarkar-Tyson M.  (2020)  Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.,  63  (22.0): [PMID:32786507] [10.1021/acs.jmedchem.0c00911]

126. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius.  (2021)  HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators,  [10.6019/CHEMBL4808148]

127. Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, Ouyang L..  (2021)  Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer.,  219  [PMID:33862514] [10.1016/j.ejmech.2021.113424]

128. Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR, Valdameri G..  (2022)  Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.,  237  [PMID:35483322] [10.1016/j.ejmech.2022.114346]

129. Pillaiyar T, Laufer S..  (2022)  Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.,  65  (2.0): [PMID:34081439] [10.1021/acs.jmedchem.1c00335]

130. Arora S, Joshi G, Chaturvedi A, Heuser M, Patil S, Kumar R..  (2022)  A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.,  65  (2.0): [PMID:34726055] [10.1021/acs.jmedchem.1c00981]

131. Oleksak P, Nepovimova E, Chrienova Z, Musilek K, Patocka J, Kuca K..  (2022)  Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).,  238  [PMID:35688004] [10.1016/j.ejmech.2022.114498]

132. Rathod B, Chak S, Patel S, Shard A..  (2021)  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.,  12  (7.0): [PMID:34355179] [10.1039/D1MD00045D]

133. Xu T, Sun D, Chen Y, Chen Y, Ouyang L..  (2020)  Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors.,  199  [PMID:32416459] [10.1016/j.ejmech.2020.112391]

134. Dunyak BM, Gestwicki JE..  (2016)  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.,  59  (21): [PMID:27409354] [10.1021/acs.jmedchem.6b00411]

135. Zhou J, Shen R, Liu J, Deng X, Xin L, Zhou HB, Huang J..  (2023)  A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.,  82  [PMID:36905762] [10.1016/j.bmc.2023.117235]

136. Sutherland JJ, Yonchev D, Fekete A, Urban L..  (2023)  A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.,  14  (1): [PMID:37468498] [10.1038/s41467-023-40064-9]

137. European Medicines Agency, 

Source

Source(18):

• Scientific Literature
• Sanger Institute Genomics of Drug Sensitivity in Cancer
• PubChem BioAssays
• Clinical Candidates
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• USP Dictionary of USAN and International Drug Names
• DrugMatrix
• TP-search Transporter Database
• AstraZeneca Deposited Data
• Curated Drug Metabolism Pathways
• Patent Bioactivity Data
• CO-ADD antimicrobial screening data
• WHO Anatomical Therapeutic Chemical Classification
• British National Formulary
• Kuster lab chemical proteomics drug profiling
• SARS-CoV-2 Screening Data 2020-21
• Fraunhofer HDAC6
• European Medicines Agency